CancerTYPE ID News & Reviews
CancerTYPE ID® Prospective Trial Published in ASCO Journal of Precision Oncology
March 19, 2018
Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of CancerTYPE ID on final diagnosis and treatment...
Study Presented at San Antonio Breast Cancer Symposium Demonstrates Strong Performance of Biotheranostics’ 92-gene Assay in the Diagnosis of
Triple Negative Breast Cancer
December 12, 2016
A study showing the strong performance of an optimized version of Biotheranostics’ 92-gene assay to accurately identify both primary and metastatic triple negative breast cancer was presented Friday, Dec. 9, at the 2016 San Antonio Breast Cancer Symposium...
Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?
The application of molecularly targeted cancer therapies has rapidly expanded in the past 2 decades. The identification of genetic mutations in tumors has led to a growing list of therapies developed to specifically target those alterations. Indeed, molecularly targeted therapies...
CancerType ID Indications for Use and Limitations
CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.